■这项研究的目的是比较脊髓刺激(SCS)和背根神经节刺激(DRG-S)治疗疼痛性糖尿病周围神经病变(PDPN)的临床结果。
■在这项前瞻性队列研究中,55例患者接受背柱脊髓刺激(SCS组),51例患者接受背根脊髓刺激(DRG-S组)。主要结果是数值评定量表(NRS)缓解率≥50%,次要结局包括SCS和DRG-S对生活质量评分(EQ-5D-3L)的影响,神经传导速度,和HbA1c,分别。
■6个月时NRS缓解率≥50%的百分比为80.43vs.79.55%,OR(95%CI):SCS和DRG-S组中的1.06(0.38-2.97),分别,12个月时VAS缓解率≥50%的百分比为79.07vs.80.95%,OR(95%CI):0.89(0.31-2.58)。与基线相比,在6个月和12个月时,EQ-5D和EQ-VAS均有显着改善(p<0.05),但SCS和DRG-S组之间的改善没有差异(p>0.05)。腓总神经传导速度,腓骨,腓浅,SCS组和PND组在术前6个月和12个月时胫神经明显改善(p<0.05)。然而,在6个月和12个月时,两组间HbA1c比较差异无统计学意义(p>0.05)。
■SCS和DRG-S均能显著改善疼痛,生活质量,PDPN患者的下肢神经传导速度,两种治疗在12个月时没有差异。
UNASSIGNED: The aim of this study was to compare the clinical outcomes of spinal cord stimulation (SCS) and dorsal root ganglion stimulation (DRG-S) in the treatment of painful diabetic peripheral neuropathy (PDPN).
UNASSIGNED: In this prospective cohort study, 55 patients received dorsal column spinal cord stimulation (SCS group) and 51 patients received dorsal root spinal cord stimulation (DRG-S group). The primary outcome was a Numerical Rating Scale (NRS) remission rate of ≥50%, and secondary outcomes included the effects of SCS and DRG-S on quality of life scores (EQ-5D-3L), nerve conduction velocity, and HbA1c, respectively.
UNASSIGNED: The percentage of NRS remission rate ≥ 50% at 6 months was 80.43 vs. 79.55%, OR (95% CI): 1.06 (0.38-2.97) in the SCS and DRG-S groups, respectively, and the percentage of VAS remission rate ≥ 50% at 12 months was 79.07 vs. 80.95%, OR (95% CI): 0.89 (0.31-2.58). Compared with baseline, there were significant improvements in EQ-5D and EQ-VAS at 6 and 12 months (p < 0.05), but there was no difference in improvement between the SCS and DRG-S groups (p > 0.05). Nerve conduction velocities of the common peroneal, peroneal, superficial peroneal, and tibial nerves were significantly improved at 6 and 12 months compared with the preoperative period in both the SCS and PND groups (p < 0.05). However, at 6 and 12 months, there was no difference in HbA1c between the two groups (p > 0.05).
UNASSIGNED: Both SCS and DRG-S significantly improved pain, quality of life, and lower extremity nerve conduction velocity in patients with PDPN, and there was no difference between the two treatments at 12 months.